Hep 3B2.1-7

Hep 3B (Liver Cancer CDX Model) 

The Hep 3B liver cancer cell line was derived from a hepatocellular carcinoma (HCC) in an 8-year-old patient. It is HBV-positive, reflecting the viral association often seen in liver cancers. Hep 3B has been widely applied in preclinical studies of HCC biology. Its reproducible tumorigenicity makes it a standard for drug development. 

Key Features: 

• Derived from hepatocellular carcinoma. 

• Hepatitis B virus–positive line. 

• Produces alpha-fetoprotein (AFP). 

• Consistent xenograft formation. 

Applications: 
Hep 3B is used to test chemotherapies and targeted agents for liver cancer. It supports biomarker studies, particularly AFP expression. Researchers apply it to understand HBV-associated oncogenesis. Its consistent performance makes it valuable for HCC translational research.